Showing results (51-60 of 222) with videos related to
Sort By:
Pageof 23
Frontiers in Oncology|September 14, 2012
Development of coagulation factor probes for the identification of procoagulant circulating tumor cellsGarth W Tormoen, Flor A Cianchetti, Paul E Bock, et al.Proceedings of the National Academy of Sciences of the United States of America|January 24, 2016
Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-κB activation and autoinflammatory diseaseJevgenia Zilberman-Rudenko, Linda Monaco Shawver, Alex W Wessel, et al.Physical Biology|October 10, 2013
Phosphatidylserine index as a marker of the procoagulant phenotype of acute myelogenous leukemia cellsGarth W Tormoen, Olivia Recht, András Gruber, et al.Biophysical Journal|July 19, 2002
Fluid shear regulates the kinetics and molecular mechanisms of activation-dependent platelet binding to colon carcinoma cellsOwen J T McCarty, Sameer Jadhav, Monica M Burdick, et al.Blood Vessels, Thrombosis & Hemostasis|September 25, 2025
Bacterial infection and activation of the contact pathway of coagulationAndré L Lira, Cristina Puy, Joseph J Shatzel, et al.Biochimica Et Biophysica Acta. Biomembranes|February 8, 2025
Lipopolysaccharide supramolecular organization regulates the activation of coagulation factor XIIAndré L Lira, Ting Liu, Joseph E Aslan, et al.Small Gtpases|January 18, 2021
Rho GTPase regulation of reactive oxygen species generation and signalling in platelet function and diseaseAnh T P Ngo, Ivan Parra-Izquierdo, Joseph E Aslan, et al.Cellular and Molecular Bioengineering|June 3, 2014
Development of a method to quantify platelet adhesion and aggregation under static conditionsSandra M Baker-Groberg, Flor A Cianchetti, Kevin G Phillips, et al.Seminars in Thrombosis and Hemostasis|June 20, 2019
The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human TrialsEmma P DeLoughery, Sven R Olson, Cristina Puy, et al.Journal of Cardiovascular Pharmacology|March 21, 2002
Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosisShaker A Mousa, James P Abulencia, Owen J T McCarty, et al.Pageof 23